   Novavax    (NASDAQ:NVAX), Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has filed for a type II variation of existing Marketing Authorization with the European Medicines Agency (EMA) for its JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. The submission is in line with guidance from EMA and the World Health Organization to target the JN.1 lineage this fall.1,2 "Novavax is working closely with European markets seeking to offer a protein-based alternative to mRNA this fall for COVID-19 vaccination," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Our updated COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3."Nonclinical data have demonstrated that Novavax's JN.1 COVID-19 vaccine induces broad neutralization responses to JN.1 lineage viruses, including those containing the F456L and R346T mutations, and to "FLiRT" and "FLuQE" variants.2-4 Novavax's vaccine also produces conserved polyfunctional, Th1-biased CD4+ T cell responses to a range of JN.1 lineage variants.2 Novavax's JN.1 COVID-19 vaccine targets the "parent strain" of KP.2 and KP.3.2 Novavax intends to have its vaccine in unit-dose vials available for distribution in the European Union for immediate release post-approval. Novavax has also filed with the U.S. Food and Drug Administration (FDA) and is working with other regulatory authorities globally on authorization or approval of its JN.1 COVID-19 vaccine.Investing.com’s ProPicks are 6 model portfolios that identify the best stocks for investors to buy now. The stocks that made the cut could produce monster returns in the coming years. Is NVAX one of them?